PALOMA-3: Subcutaneous Amivantamab + Lazertinib for EGFR+ NSCLC
Joshua K. Sabari, MD, and Martin Dietrich, MD, PhD, examine both the evolution of first-line EGFR TKIs as standard treatment for EGFR-mutated metastatic non-small cell lung cancer and the ongoing clinical challenges in managing resistance, toxicities, and treatment sequencing in this space.
EP. 1: EGFR mNSCLC Front-Line: Treatment Options
December 23rd 2024A panelist discusses how targeted therapies such as EGFR tyrosine kinase inhibitors have become the standard first-line treatment for patients with EGFR-mutated metastatic non–small cell lung cancer, offering improved outcomes compared with traditional chemotherapy.
EP. 2: EGFR mNSCLC: Challenges with Treatments in this Space
January 3rd 2025A panelist discusses how managing resistance mechanisms and toxicity profiles and identifying optimal sequencing strategies remain key challenges in treating EGFR-mutated metastatic non–small cell lung cancer despite advances in targeted therapies.
EP. 3: EGFR mNSCLC Front-Line Treatment Options: Challenges and AEs
January 28th 2025Panelists discuss how managing adverse events and selecting optimal treatment strategies remain key challenges in front-line EGFR-mutated, non–small cell lung cancer (mNSCLC) therapy, particularly when weighing the efficacy and toxicity profiles of available targeted therapies.
EP. 4: PALOMA-3: Study Design and Baseline Characteristics
January 28th 2025Panelists discuss how PALOMA-3, a phase 3 randomized clinical trial, was designed to evaluate palbociclib plus fulvestrant vs placebo plus fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had progressed on prior endocrine therapy.
